• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.

作者信息

Herrgott Ilka, Riemekasten Gabriela, Hunzelmann Nicolas, Sunderkötter Cord

机构信息

Department of Dermatology, University Hospital Münster, Münster, Germany.

出版信息

Rheumatol Int. 2008 Aug;28(10):1023-9. doi: 10.1007/s00296-008-0556-1. Epub 2008 Mar 5.

DOI:10.1007/s00296-008-0556-1
PMID:18320192
Abstract

Major cutaneous vascular complications of systemic sclerosis (SSc) are secondary Raynaud's phenomenon (RP) and digital ulcers. Even though SSc is a rare disease, timely and appropriate management of its vascular complications is mandatory for reducing the rate of major impairment. It should therefore be aware to physicians from different specialties. We evaluated the diagnostic and therapeutic approach toward secondary RP and ulceration in SSc patients at 28 German clinical centers at the time of initiation of the German network for Systemic Scleroderma (DNSS). We retrieved data via questionnaires and from the DNSS patient registry. Management of RP and ulcerations in SSc were heterogeneous at initiation of the network, reflecting a sometimes insufficient use of the diagnostic and therapeutic possibilities. As such, (1) calcium channel blockers were the first line therapy in most centers; but often in insufficient dosages, and (2) only 21.2% of patients with acral ulceration had received prostacyclins when recruited into the network. The sometimes insufficient care of vascular complications of SSc in Germany revealed the need for their standardized management, e.g. within a network for SSc and for consensus on a diagnostic or therapeutic algorithm.

摘要

相似文献

1
Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.
Rheumatol Int. 2008 Aug;28(10):1023-9. doi: 10.1007/s00296-008-0556-1. Epub 2008 Mar 5.
2
Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.系统性硬化症的雷诺现象和指(趾)溃疡的管理。
Joint Bone Spine. 2011 Jul;78(4):341-6. doi: 10.1016/j.jbspin.2010.11.005. Epub 2010 Dec 22.
3
Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.他汀类药物:可能对系统性硬化症相关的雷诺现象和指端溃疡的治疗有用。
J Rheumatol. 2008 Sep;35(9):1801-8. Epub 2008 Aug 15.
4
Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.一项研究评估了西地那非在系统性硬化症相关肺动脉高压和皮肤血管并发症中的安全性和疗效:前瞻性、开放标签、非对照的初步研究。
Rheumatol Int. 2013 Apr;33(4):1047-52. doi: 10.1007/s00296-012-2466-5. Epub 2012 Jul 26.
5
[Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany].[德国系统性硬化症所致肢端循环障碍患者住院使用前列环素衍生物进行血管活性治疗的实际情况]
Z Rheumatol. 2020 Dec;79(10):1057-1066. doi: 10.1007/s00393-019-00743-9.
6
Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment.内皮剪切应力对系统性硬化症血管病变和治疗的影响。
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):175-182. doi: 10.55563/clinexprheumatol/7ulgbj. Epub 2018 Sep 20.
7
Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.静脉注射伊洛前列素治疗雷诺现象和系统性硬化症相关的指端溃疡的实用建议:系统文献回顾和专家共识。
Semin Arthritis Rheum. 2019 Feb;48(4):686-693. doi: 10.1016/j.semarthrit.2018.03.019. Epub 2018 Apr 4.
8
Systematic literature review to inform the Portuguese recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases.系统文献回顾,为葡萄牙制定的系统性硬化症和其他结缔组织疾病的雷诺现象和指(趾)溃疡管理建议提供信息。
ARP Rheumatol. 2024 Jul 1;3(Apr-Jun):128-144. doi: 10.63032/YHBL8967.
9
Raynaud, digital ulcers and calcinosis in scleroderma.硬皮病中的雷诺现象、指端溃疡和钙质沉着
Reumatol Clin. 2012 Sep-Oct;8(5):270-7. doi: 10.1016/j.reuma.2012.02.006. Epub 2012 Jul 25.
10
The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.雷诺现象症状特征在系统性硬化症中的临床相关性。
Clin Rheumatol. 2022 Oct;41(10):3049-3054. doi: 10.1007/s10067-022-06206-y. Epub 2022 May 18.

引用本文的文献

1
The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.2024 年英国风湿病学会系统性硬化症管理指南。
Rheumatology (Oxford). 2024 Nov 1;63(11):2956-2975. doi: 10.1093/rheumatology/keae394.
2
The patient experience of Raynaud's phenomenon in systemic sclerosis.系统性硬皮病患者的雷诺现象体验。
Rheumatology (Oxford). 2019 Jan 1;58(1):18-26. doi: 10.1093/rheumatology/key026.
3
Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

本文引用的文献

1
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.系统性硬化症器官表现的临床风险评估:来自欧洲抗风湿病联盟硬皮病试验与研究组数据库的报告
Ann Rheum Dis. 2007 Jun;66(6):754-63. doi: 10.1136/ard.2006.062901. Epub 2007 Jan 18.
2
Vasoactive therapies in systemic sclerosis.系统性硬化症中的血管活性疗法。
Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii49-51. doi: 10.1093/rheumatology/kel283.
3
Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.
雷诺现象与手指缺血:风险分层、诊断及管理的实用方法
Int J Clin Rheumtol. 2010;5(3):355-370. doi: 10.2217/ijr.10.17.
4
Registry evaluation of digital ulcers in systemic sclerosis.系统性硬化症中数字溃疡的登记评估
Int J Rheumatol. 2010;2010. doi: 10.1155/2010/363679. Epub 2010 Aug 25.
与系统性硬化症相关的雷诺现象的病理生理学及临床后果
Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii33-5. doi: 10.1093/rheumatology/kel280.
4
[Raynaud phenomenon in dermatology : Part 2: therapy].[皮肤科的雷诺现象:第2部分:治疗]
Hautarzt. 2006 Oct;57(10):927-38; quiz 941. doi: 10.1007/s00105-006-1218-4.
5
[Evidence-based therapy of Raynaud's syndrome].[雷诺综合征的循证治疗]
Z Rheumatol. 2006 Jul;65(4):285-9. doi: 10.1007/s00393-006-0068-x.
6
Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.硬皮病中雷诺现象和指端缺血性病变的管理
Rheum Dis Clin North Am. 2003 May;29(2):293-313. doi: 10.1016/s0889-857x(03)00019-x.
7
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.测量硬皮病和雷诺现象患者的疾病活动度和功能状态。
Arthritis Rheum. 2002 Sep;46(9):2410-20. doi: 10.1002/art.10486.
8
Ulnar artery involvement in systemic sclerosis (scleroderma).尺动脉受累于系统性硬化症(硬皮病)。
J Rheumatol. 2002 Jan;29(1):102-6.
9
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.用于系统性硬化症中雷诺现象的钙通道阻滞剂。
Arthritis Rheum. 2001 Aug;44(8):1841-7. doi: 10.1002/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8.
10
Raynaud's phenomenon.雷诺现象
Lancet. 2001 Jun 23;357(9273):2042-8. doi: 10.1016/S0140-6736(00)05118-7.